DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rinucumab
Rinucumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
The Two Tontti Tudiul Lui Hi Ha Unit
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
Stembook 2018.Pdf
WHO INN Proposed List
(INN) for Biological and Biotechnological Substances
Strategies to Obtain Diverse and Specific Human Monoclonal
EXTENDED-DURATION THERAPEUTICS for TREATMENT of WET AMD Promising Treatment Options Under Investigation May Someday Lead to More Successful Disease Management
The Following List Contains the Classification Decisions Taken
Emtree Terms Changed in September 2013
Regeneron Pharmaceuticals, Inc
New Treatment Modalities for Neovascular Age-Related Macular
Multiple Myeloma Would Make Good Guinea Pig for Oncology Cost Control
Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
Tumor Angiogenesis Revisited: Regulators and Clinical Implications
WO 2017/024062 Al 9 February 2017 (09.02.2017) P O P C T
Top View
Anti-CD160, Alone Or in Combination with Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
Age-Related Macular Degeneration
2015 Annual Report 3 Dear Shareholders
REGENERON PHARMACEUTICALS INC Form 10-K Annual Report Filed
Regeneron Pharmaceuticals Inc
View Annual Report
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT